New directions in the basic and translational biology of interleukin-27

Trends in Immunology

Volumn 33, Issue 2, 2012, Pages 91-97

  Wojno, Elia D Tait ^a   Hunter, Christopher A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 21; INTERLEUKIN 27; INTERLEUKIN 27P28; INTERLEUKIN 6; STAT1 PROTEIN; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; BIOLOGY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; HELPER CELL; HUMAN; NATURAL KILLER CELL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; TH1 CELL; TH17 CELL; TH2 CELL; UPREGULATION;

ANIMALS; CELL DIFFERENTIATION; HUMANS; IMMUNITY, HUMORAL; INTERLEUKIN-17; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, REGULATORY;

EID: 84856554638     PISSN: 14714906     EISSN: 14714981     Source Type: Journal    
DOI: 10.1016/j.it.2011.11.003     Document Type: Review

References (108)

1. Pflanz S., et al. IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4(+) T cells. Immunity 2002, 16:779-790.
2. Pflanz S., et al. WSX-1 and glycoprotein 130 constitute a signal-transducing receptor for IL-27. J. Immunol. 2004, 172:2225-2231.
3. Villarino A.V., et al. Positive and negative regulation of the IL-27 receptor during lymphoid cell activation. J. Immunol. 2005, 174:7684-7691.
4. Scheller J., et al. No inhibition of IL-27 signaling by soluble gp130. Biochem. Biophys. Res. Commun. 2005, 326:724-728.
5. Stumhofer J.S., Hunter C.A. Advances in understanding the anti-inflammatory properties of IL-27. Immunol. Lett. 2008, 117:123-130.
6. Villarino A., et al. The IL-27R (WSX-1) is required to suppress T cell hyperactivity during infection. Immunity 2003, 19:645-655.
7. Hamano S., et al. WSX-1 is required for resistance to Trypanosoma cruzi infection by regulation of proinflammatory cytokine production. Immunity 2003, 19:657-667.
8. Awasthi A., et al. A dominant function for interleukin 27 in generating interleukin 10-producing anti-inflammatory T cells. Nat. Immunol. 2007, 8:1380-1389.
9. Fitzgerald D.C., et al. Suppression of autoimmune inflammation of the central nervous system by interleukin 10 secreted by interleukin 27-stimulated T cells. Nat. Immunol. 2007, 8:1372-1379.
10. Stumhofer J.S., et al. Interleukins 27 and 6 induce STAT3-mediated T cell production of interleukin 10. Nat. Immunol. 2007, 8:1363-1371.
11. Brombacher F., et al. Novel IL-12 family members shed light on the orchestration of Th1 responses. Trends Immunol. 2003, 24:207-212.
12. Trinchieri G., et al. The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses. Immunity 2003, 19:641-644.
13. Hunter C.A. New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions. Nat. Rev. Immunol. 2005, 5:521-531.
14. Batten M., Ghilardi N. The biology and therapeutic potential of interleukin 27. J. Mol. Med. 2007, 85:661-672.
15. Moore K.W., et al. Interleukin-10 and the interleukin-10 receptor. Annu. Rev. Immunol. 2001, 19:683-765.
16. Roncarolo M.G., et al. Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol. Rev. 2006, 212:28-50.
17. Murugaiyan G., et al. IL-27 is a key regulator of IL-10 and IL-17 production by human CD4+ T cells. J. Immunol. 2009, 183:2435-2443.
18. Cao S., et al. The protooncogene c-Maf is an essential transcription factor for IL-10 gene expression in macrophages. J. Immunol. 2005, 174:3484-3492.
19. Xu J., et al. c-Maf regulates IL-10 expression during Th17 polarization. J. Immunol. 2009, 182:6226-6236.
20. Saraiva M., et al. Interleukin-10 production by Th1 cells requires interleukin-12-induced STAT4 transcription factor and ERK MAP kinase activation by high antigen dose. Immunity 2009, 31:209-219.
21. Rochman Y., et al. New insights into the regulation of T cells by gamma(c) family cytokines. Nat. Rev. Immunol. 2009, 9:480-490.
22. Pot C., et al. Cutting edge: IL-27 induces the transcription factor c-Maf, cytokine IL-21, and the costimulatory receptor ICOS that coordinately act together to promote differentiation of IL-10-producing Tr1 cells. J. Immunol. 2009, 183:797-801.
23. Apetoh L., et al. The aryl hydrocarbon receptor interacts with c-Maf to promote the differentiation of type 1 regulatory T cells induced by IL-27. Nat. Immunol. 2010, 11:854-861.
24. Wang H., et al. IL-27 induces the differentiation of Tr1-like cells from human naive CD4+ T cells via the phosphorylation of STAT1 and STAT3. Immunol. Lett. 2011, 136:21-28.
25. Ilarregui J.M., et al. Tolerogenic signals delivered by dendritic cells to T cells through a galectin-1-driven immunoregulatory circuit involving interleukin 27 and interleukin 10. Nat. Immunol. 2009, 10:981-991.
26. Shiokawa A., et al. IL-10 and IL-27 producing dendritic cells capable of enhancing IL-10 production of T cells are induced in oral tolerance. Immunol. Lett. 2009, 125:7-14.
27. Murugaiyan G., et al. Identification of an IL-27/osteopontin axis in dendritic cells and its modulation by IFN-gamma limits IL-17-mediated autoimmune inflammation. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:11495-11500.
28. Lee Y.S., et al. Retinal cells suppress intraocular inflammation (uveitis) through production of interleukin-27 and interleukin-10. Immunology 2011, 132:492-502.
29. Sun J., et al. CD4+ T cell help and innate-derived IL-27 induce Blimp-1-dependent IL-10 production by antiviral CTLs. Nat. Immunol. 2011, 12:327-334.
30. Iyer S.S., et al. Lipopolysaccharide-mediated IL-10 transcriptional regulation requires sequential induction of type I IFNs and IL-27 in macrophages. J. Immunol. 2010, 185:6599-6607.
31. Crotty S. Follicular helper CD4 T cells (TFH). Annu. Rev. Immunol. 2011, 29:621-663.
32. Bauquet A.T., et al. The costimulatory molecule ICOS regulates the expression of c-Maf and IL-21 in the development of follicular T helper cells and TH-17 cells. Nat. Immunol. 2009, 10:167-175.
33. Ise W., et al. The transcription factor BATF controls the global regulators of class-switch recombination in both B cells and T cells. Nat. Immunol. 2011, 12:536-543.
34. Hiramatsu Y., et al. c-Maf activates the promoter and enhancer of the IL-21 gene, and TGF-beta inhibits c-Maf-induced IL-21 production in CD4+ T cells. J. Leuk. Biol. 2010, 87:703-712.
35. Nurieva R.I., et al. Generation of T follicular helper cells is mediated by interleukin-21 but independent of T helper 1, 2, or 17 cell lineages. Immunity 2008, 29:138-149.
36. Linterman M.A., et al. IL-21 acts directly on B cells to regulate Bcl-6 expression and germinal center responses. J. Exp. Med. 2010, 207:353-363.
37. Batten M., et al. IL-27 supports germinal center function by enhancing IL-21 production and the function of T follicular helper cells. J. Exp. Med. 2010, 207:2895-2906.
38. Artis D., et al. Cutting edge: early IL-4 production governs the requirement for IL-27-WSX-1 signaling in the development of protective Th1 cytokine responses following Leishmania major infection. J. Immunol. 2004, 172:4672-4675.
39. Miyazaki Y., et al. Exacerbation of experimental allergic asthma by augmented Th2 responses in WSX-1-deficient mice. J. Immunol. 2005, 175:2401-2407.
40. Shimizu S., et al. Membranous glomerulonephritis development with Th2-type immune deviations in MRL/lpr mice deficient for IL-27 receptor (WSX-1). J. Immunol. 2005, 175:7185-7192.
41. Yoshimoto T., et al. Induction of IgG2a class switching in B cells by IL-27. J. Immunol. 2004, 173:2479-2485.
42. Boumendjel A., et al. IL-27 induces the production of IgG1 by human B cells. Eur. Cytokine Netw. 2006, 17:281-289.
43. Larousserie F., et al. Differential effects of IL-27 on human B cell subsets. J. Immunol. 2006, 176:5890-5897.
44. Canale S., et al. Interleukin-27 inhibits pediatric B-acute lymphoblastic leukemia cell spreading in a preclinical model. Leukemia 2011, 10.1038/leu.2011.158.
45. Bluestone J.A., Tang Q. How do CD4+CD25+ regulatory T cells control autoimmunity?. Curr. Opin. Immunol. 2005, 17:638-642.
46. Wohlfert E., Belkaid Y. Plasticity of T reg at infected sites. Mucosal Immunol. 2010, 3:213-215.
47. Belkaid Y., Oldenhove G. Tuning microenvironments: induction of regulatory T cells by dendritic cells. Immunity 2008, 29:362-371.
48. Miyara M., Sakaguchi S. Natural regulatory T cells: mechanisms of suppression. Trends Mol. Med. 2007, 13:108-116.
49. Neufert C., et al. IL-27 controls the development of inducible regulatory T cells and Th17 cells via differential effects on STAT1. Eur. J. Immunol. 2007, 37:1809-1816.
50. Stumhofer J.S., et al. Negative regulation of Th17 responses. Semin. Immunol. 2007, 19:394-399.
51. Huber M., et al. IL-27 inhibits the development of regulatory T cells via STAT3. Int. Immunol. 2008, 20:223-234.
52. Owaki T., et al. IL-27 suppresses CD28-medicated IL-2 production through suppressor of cytokine signaling 3. J. Immunol. 2006, 176:2773-2780.
53. Villarino A.V., et al. IL-27 limits IL-2 production during Th1 differentiation. J. Immunol. 2006, 176:237-247.
54. Malek T.R. The main function of IL-2 is to promote the development of T regulatory cells. J. Leuk. Biol. 2003, 74:961-965.
55. Salcedo R., et al. Immunologic and therapeutic synergy of IL-27 and IL-2: enhancement of T cell sensitization, tumor-specific CTL reactivity and complete regression of disseminated neuroblastoma metastases in the liver and bone marrow. J. Immunol. 2009, 182:4328-4338.
56. Cox J.H., et al. IL-27 promotes T cell-dependent colitis through multiple mechanisms. J. Exp. Med. 2011, 208:115-123.
57. Yang X.O., et al. Molecular antagonism and plasticity of regulatory and inflammatory T cell programs. Immunity 2008, 29:44-56.
58. Tait Wojno E.D., et al. A Role for IL-27 in limiting T regulatory cell populations. J. Immunol. 2011, 187:266-273.
59. Batten M., et al. Interleukin 27 limits autoimmune encephalomyelitis by suppressing the development of interleukin 17-producing T cells. Nat. Immunol. 2006, 7:929-936.
60. Goodman W.A., et al. Stat3 phosphorylation mediates resistance of primary human T cells to regulatory T cell suppression. J. Immunol. 2011, 186:3336-3345.
61. McAleer J.P., et al. The WSX-1 pathway restrains intestinal T-cell immunity. Int. Immunol. 2011, 23:129-137.
62. Boulay J.L., et al. Molecular phylogeny within type I cytokines and their cognate receptors. Immunity 2003, 19:159-163.
63. Heinrich P.C., et al. Interlukin-6-type cytokine signaling through the gp130/Jak/STAT pathway. Biochem. J. 1998, 334:297-314.
64. Niedbala W., et al. IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells. Eur. J. Immunol. 2007, 37:3021-3029.
65. Collison L.W., et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 2007, 450:566-569.
66. Collison L.W., et al. IL-35-mediated induction of a potent regulatory T cell population. Nat. Immunol. 2010, 11:1093-1101.
67. Devergne O., et al. Epstein-Barr virus-induced gene 3 and the p35 subunit of interleukin 12 form a novel heterodimeric hematopoietin. Proc. Natl. Acad. Sci. U.S.A. 1997, 94:12041-12046.
68. Crabe S., et al. The IL-27 p28 subunit binds cytokine-like factor 1 to form a cytokine regulating NK and T cell activities requiring IL-6R for signaling. J. Immunol. 2009, 183:7692-7702.
69. Shimozato O., et al. The secreted form of p28 subunit of interleukin (IL)-27 inhibits biological functions of IL-27 and suppresses anti-allogeneic immune responses. Immunology 2009, 128:e816-e825.
70. Rousseau F., et al. IL-27 structural analysis demonstrates similarities with ciliary neurotrophic factor (CNTF) and leads to the identification of antagonistic variants. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:19420-19425.
71. Stumhofer J.S., et al. A role for IL-27p28 as an antagonist of gp130-mediated signaling. Nat. Immunol. 2010, 11:1119-1126.
72. Brusko T.M., et al. Human regulatory T cells: role in autoimmune disease and therapeutic opportunities. Immunol. Rev. 2008, 223:371-390.
73. Sakaguchi S., Powrie F. Emerging challenges in regulatory T cell function and biology. Science 2007, 317:627-629.
74. Jaron B., et al. Effect of attenuation of Treg during BCG immunization on anti-mycobacterial Th1 responses and protection against Mycobacterium tuberculosis. PLoS ONE 2008, 3:e2833.
75. Ruter J., et al. Altering regulatory T cell function in cancer immunotherapy: a novel means to boost the efficacy of cancer vaccines. Front. Biosci. 2009, 14:1761-1770.
76. Hisada M., et al. Potent antitumor activity of interleukin-27. Cancer Res. 2004, 64:1152-1156.
77. Salcedo R., et al. IL-27 mediates complete regression of orthotopic primary and metastatic murine neuroblastoma tumors: role for CD8+ T cells. J. Immunol. 2004, 173:7170-7182.
78. Cao Y., et al. IL-27 induces a Th1 immune response and susceptibility to experimental arthritis. J. Immunol. 2008, 180:922-930.
79. Mayer K.D., et al. Cutting edge: T-bet and IL-27R are critical for in vivo IFN-gamma production by CD8 T cells during infection. J. Immunol. 2008, 180:693-697.
80. Schneider R., et al. IL-27 increases the proliferation and effector functions of human naive CD8+ T lymphocytes and promotes their development into Tc1 cells. Eur. J. Immunol. 2011, 41:47-59.
81. Yoshimoto T., et al. Antiproliferative activity of IL-27 on melanoma. J. Immunol. 2008, 180:6527-6535.
82. Ho M.Y., et al. IL-27 directly restrains lung tumorigenicity by suppressing cyclooxygenase-2-mediated activities. J. Immunol. 2009, 183:6217-6226.
83. Cocco C., et al. Interleukin-27 acts as multifunctional antitumor agent in multiple myeloma. Clin. Cancer Res. 2010, 16:4188-4197.
84. Sasaoka T., et al. Treatment with IL-27 attenuates experimental colitis through the suppression of the development of IL-17-producing T helper cells. Am. J. Physiol. Gastroenterol. Liver Physiol. 2011, 300:G568-G576.
85. Rajaiah R., et al. Interleukin-27 and interferon-gamma are involved in regulation of autoimmune arthritis. J. Biol. Chem. 2011, 286:2817-2825.
86. Niedbala W., et al. Interleukin 27 attenuates collagen-induced arthritis. Ann. Rheum. Dis. 2008, 67:1474-1479.
87. Fitzgerald D.C., et al. Suppressive effect of IL-27 on encephalitogenic Th17 cells and the effector phase of experimental autoimmune encephalomyelitis. J. Immunol. 2007, 179:3268-3275.
88. Miyazaki Y., et al. Amelioration of delayed-type hypersensitivity responses by IL-27 administration. Biochem. Biophys. Res. Commun. 2008, 373:397-402.
89. Yoshimoto T., et al. IL-27 suppresses Th2 cell development and Th2 cytokines production from polarized Th2 cells: a novel therapeutic way for Th2-mediated allergic inflammation. J. Immunol. 2007, 179:4415-4423.
90. Silver J.S., Hunter C.A. gp130 at the nexus of inflammation, autoimmunity, and cancer. J. Leuk. Biol. 2010, 88:1145-1156.
91. Chae S.C., et al. Identification of polymorphisms in human interleukin-27 and their association with asthma in a Korean population. J. Hum. Genet. 2007, 52:355-361.
92. Imielinski M., et al. Common variants at five new loci associated with early-onset inflammatory bowel disease. Nat. Genet. 2009, 41:1335-1340.
93. Li C.S., et al. Interleukin-27 polymorphisms are associated with inflammatory bowel diseases in a Korean population. J. Gastroenterol. Hepatol. 2009, 24:1692-1696.
94. Hutloff A., et al. ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28. Nature 1999, 397:263-266.
95. Spolski R., et al. IL-21 mediates suppressive effects via its induction of IL-10. J. Immunol. 2009, 182:2859-2867.
96. Poholek A.C., et al. In vivo regulation of Bcl6 and T follicular helper cell development. J. Immunol. 2010, 185:313-326.
97. Eto D., et al. IL-21 and IL-6 are critical for different aspects of B cell immunity and redundantly induce optimal follicular helper CD4 T cell (Tfh) differentiation. PLoS ONE 2011, 6:e17739.
98. Josefowicz S.Z., Rudensky A. Control of regulatory T cell lineage commitment and maintenance. Immunity 2009, 30:616-625.
99. Herman A.E., et al. CD4+CD25+ T regulatory cells dependent on ICOS promote regulation of effector cells in the prediabetic lesion. J. Exp. Med. 2004, 199:1479-1489.
100. Yang X.O., et al. Regulation of inflammatory responses by IL-17F. J. Exp. Med. 2008, 205:1063-1075.
101. Collison L.W., et al. Regulatory T cell suppression is potentiated by target T cells in a cell contact, IL-35- and IL-10-dependent manner. J. Immunol. 2009, 182:6121-6128.
102. Kochetkova I., et al. IL-35 stimulation of CD39+ regulatory T cells confers protection against collagen II-induced arthritis via the production of IL-10. J. Immunol. 2010, 184:7144-7153.
103. Huang C.H., et al. Airway inflammation and IgE production induced by dust mite allergen-specific memory/effector Th2 cell line can be effectively attenuated by IL-35. J. Immunol. 2011, 187:462-471.
104. Liu F., et al. Detectable expression of IL-35 in CD4+ T cells from peripheral blood of chronic hepatitis B patients. Clin. Immunol. 2011, 139:1-5.
105. Chaturvedi V., et al. Cutting edge: human regulatory T cells require IL-35 to mediate suppression and infectious tolerance. J. Immunol. 2011, 186:6661-6666.
106. Bardel E., et al. Human CD4+ CD25+ Foxp3+ regulatory T cells do not constitutively express IL-35. J. Immunol. 2008, 181:6898-6905.
107. Tong H., et al. Exacerbation of delayed-type hypersensitivity responses in EBV-induced gene-3 (EBI-3)-deficient mice. Immunol. Lett. 2010, 128:108-115.
108. Kuo J., et al. Interleukin-35 enhances lyme arthritis in borrelia-vaccinated and -infected mice. Clin. Vaccine Immunol. 2011, 18:1125-1132.